Trial Profile

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Exemestane
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms ARIANNA

Most Recent Events

25 Oct 2022 Status changed from recruiting to discontinued.
22 Jun 2022 Planned End Date changed from 30 Jan 2023 to 2 Jul 2023.
22 Jun 2022 Planned primary completion date changed from 30 Mar 2022 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com